Get the Stockscreener App
9.47
3.37%
-0.33
Inmune Bio Inc stock is traded at $9.47, with a volume of 205.41K.
It is down -3.37% in the last 24 hours and up +70.02% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$9.80
Open:
$9.8
24h Volume:
205.41K
Relative Volume:
0.65
Market Cap:
$217.29M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-5.6707
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-6.79%
1M Performance:
+70.02%
6M Performance:
+34.33%
1Y Performance:
-25.55%
1-Day Range:
$9.36
$10.02
1-Week Range:
$8.70
$10.50
52-Week Range:
$4.32
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
9.4467 | 217.29M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.98 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.32 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Expands By 7.0% - MarketBeat
INmune Bio Inc (INMB) shows promising results - US Post News
Trading Day Review: INmune Bio Inc (INMB) Loses Momentum, Closing at 9.31 - The Dwinnex
Analyzing INmune Bio Inc (INMB) After Recent Trading Activity - Knox Daily
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in January - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
(INMB) Proactive Strategies - Stock Traders Daily
INmune Bio (NASDAQ:INMB) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
INmune Bio advances prostate cancer trial at VA Hospital By Investing.com - Investing.com South Africa
BTIG maintains INmune Bio stock Buy rating and $21 target By Investing.com - Investing.com Australia
BTIG maintains INmune Bio stock Buy rating and $21 target - MSN
INmune Bio advances prostate cancer trial at VA Hospital - Investing.com
Rodman & Renshaw sets INmune Bio stock Buy rating, $23 target - Investing.com
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans - The Manila Times
Groundbreaking NK Cell Cancer Treatment Now Available to Veterans: Major Trial Expansion - StockTitan
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Market Highlights: Rocket Lab USA Inc (RKLB) Ends on a High Note at 31.57 - The Dwinnex
C-Suite Buy of the Week: Executive Moves from Biotech to Banking - Benzinga
INmune Bio Insiders Added US$902.6k Of Stock To Their Holdings - Simply Wall St
Mason Resources (CVE:LLG) Stock Crosses Above 200 Day Moving Average – Should You Sell? - Defense World
Flanigan’s Enterprises (NYSEAMERICAN:BDL) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Barclays PLC Boosts Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
(INMB) Investment Analysis and Advice - Stock Traders Daily
14,725 Shares in INmune Bio, Inc. (NASDAQ:INMB) Bought by Jane Street Group LLC - Defense World
Candel Therapeutics (NASDAQ:CADL) versus INmune Bio (NASDAQ:INMB) Head-To-Head Review - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Average Target Price from Analysts - Defense World
Praetorian PR LLC Increases Stake in INmune Bio Inc: A Strategic Move in Biotechnology - GuruFocus.com
How Do Things Look For INmune Bio Inc (NASDAQ: INMB) In The Short-Term? - Stocks Register
Analysts’ Revisions Show Improving Sentiment For Uranium Energy Corp (AMEX: UEC) - Stocks Register
How Do Things Look For Lithium Americas Corp (NewCo) (NYSE: LAC) In The Short-Term? - Stocks Register
What Did We Note About Insider Trading At AT&T, Inc (NYSE: T)? - Stocks Register
Watch Duty was downloaded 2 million times during this week’s LA fires - Yahoo! Voices
Retail investors account for 41% of TELA Bio, Inc.'s (NASDAQ:TELA) ownership, while institutions account for 28% - Yahoo Finance
Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
How To Trade (INMB) - Stock Traders Daily
Immunis Closes $25 Million Series A-1 Financing Round - Yahoo Finance
ChargePoint Holdings, Inc. (CHPT) Stock Moves -0.89%: What You Should Know - Yahoo Finance
Astera Labs, Inc. (ALAB) Stock Moves -0.82%: What You Should Know - Yahoo Finance
Palantir Technologies Inc. (PLTR) Stock Moves -1.44%: What You Should Know - Yahoo Finance
Nu Holdings Ltd. (NU) Declines More Than Market: Some Information for Investors - Yahoo Finance
IGM Bio stock plunges as analysts downgrade (IGMS:NASDAQ) - Seeking Alpha
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? - Yahoo Finance
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine - Yahoo Finance
Moon Capital Management Liquidated CVS Health Corporation (CVS) with Modest Gain - Yahoo Finance
BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency - Yahoo Finance
Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases - Yahoo Finance
Is BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued? - Yahoo Finance
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy - Yahoo Finance
Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board - Yahoo Finance
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
| Juda Scott | Director |
Jun 25 '24 |
Buy |
7.27 |
5,000 |
36,350 |
71,603 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):